DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the DISHMAN CARBO AMCIS LTD (DCAL) share price today?

DISHMAN CARBO AMCIS LTD (DCAL) is trading at ₹191.46 on the NSE, down 1.37% on the day. Source: DocStoX.

What is the PE ratio of DISHMAN CARBO AMCIS LTD?

DISHMAN CARBO AMCIS LTD has a price-to-earnings (PE) ratio of 30.8 in the Healthcare sector.

What is the market capitalisation of DISHMAN CARBO AMCIS LTD?

DISHMAN CARBO AMCIS LTD has a market capitalisation of approximately ₹3,039 crore.

DISHMAN CARBO AMCIS LTD

DCAL·NSE·Healthcare

₹191.46▼ -2.65 (-1.37%)

Healthcare · Pharmaceuticals

A steady, established business

Day₹189.11

₹193.60

52W₹129

₹32233%

Open

₹193.32

High

₹193.60

Low

₹189.11

Prev Close

₹194.11

Volume

2.45L

VWAP

₹191.06

Snapshot

Key fundamentals

Market Cap

₹3,039 Cr

P/E Ratio

30.78Fair

P/B Ratio

0.44

EPS

₹6.22

Book Value

₹426.00

ROE

1.58%Weak

ROCE

3.00%Weak

Dividend Yield

0.00%

Debt / Equity

0.46Moderate

Face Value

₹2.00

52W High

₹321.95

52W Low

₹128.50

Sector

Healthcare

Industry

Pharmaceuticals

Expensive

None moatMedium uncertainty

Fair value estimate

₹340

▲ 77.7%upside

Trading at ₹191 — 78% below our estimate

BearFair valueBull

₹244₹340₹391

/100

Business quality — Watch the fundamentals

Growth 27Profitability 4Efficiency 0Valuation 63

Plain English

Our view

A steady, established business
Low debt relative to equity
Weak returns on equity (2%)

Strengths

Low debt relative to equity
Promoters hold a controlling stake

Risks

Weak returns on equity (2%)
Fundamental red flags (Piotroski 2/9)

How we got there

Fair value methods

Residual income

2% ROE fading to 13% over ~3 yrs, on ₹426 book

₹367

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹244

Analyst target

No analyst coverage

—

Blended fair value₹340

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Promoters hold a controlling stake

Bear case

Weak returns on equity (2%)
Fundamental red flags (Piotroski 2/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

30.8Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

1.6%Weak

Above 15% is considered healthy for Indian equities

ROCE

3.0%Weak

Above 18% means capital is working hard

Debt/Eq

0.46Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹3,039 Cr

P/B

0.44

EPS

₹6.22

Div Yield

—

What changed

Recent changes

Foreign investors-0.2% stake last quarter
Domestic institutions+0.4% stake last quarter

What matters

News impact

Overview

Valuation

Reasonable

P/E 30.8×

Growth

Steady

+7% rev CAGR

Profitability

Modest

1.6% ROE

Financial health

Comfortable

D/E 0.46

Momentum

N/A

No technicals

Today

Trading activity

Delivery %59.3%

Turnover₹467.56L Cr

Trades2,822

VWAP₹191.06

Face value₹2.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+6.7%

+8.9%

10Y

+82.9%

Profit

—

10Y

+58.0%

EPS

—

10Y

—

Profile

Pros

Stock is trading at 0.46 times its book value
Company has delivered good profit growth of 20.9% CAGR over last 5 years

Watch-outs

Cons

Though the company is reporting repeated profits, it is not paying out dividend
Company has low interest coverage ratio.
The company has delivered a poor sales growth of 8.93% over past five years.
Company has a low return on equity of -0.40% over last 3 years.
Company might be capitalizing the interest cost

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors sold 0.21 pts; domestic institutions added 0.36 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

59%

Promoter

Promoters

59.3%0.00

Public

31.6%-0.15

FII / FPI

7.5%-0.21

DII

1.6%+0.36

Total shareholders

49,009+528 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter59.32%

FII7.45%

DII1.63%

Public31.60%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions